This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the hypofractionated high dose radiation therapy and a rationale for adjuvant immunotherapy.
* Patient information and collection of a signed informed consent form * Clinical data collection * Blood samples of 35 mL: 1. after registration, prior to the first fraction of radiotherapy 2. within 15 minutes after the administration of the 1st, the 2nd and the 3rd radiotherapy sessions 3. one week, 3 months, 6 months, 9 months and 12 months after the last radiotherapy session * Storage of the blood samples at ambient temperature * Transportation of the samples to the Institute of Biology of Lille (IBL) - CNRS UMR8161 for analysis * Destruction of the samples at the end of the analysis
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
28
Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment. Before radiotherapy: * Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy
* Sample T1: within 15 minutes after the administration of the first fraction, * Sample T2: within 15 minutes after the administration of the second fraction, * Sample T3: within 15 minutes after the administration of the third fraction
Centre Oscar Lambret
Lille, France
Analyse of immunological parameters, decription of secreted markers and nanovesicles production
Description and evolution of cell fraction, quantification of immune cells, verification of the presence and evolution of activation markers and quantification of secreted exosomes ; before, during and after radiotherapy
Time frame: from baseline to 1 year follow up
Cell viability, determined by number of live/dead cells present
Cell viability and cell proliferation
Time frame: from baseline to 1 year follow up
Progression-free rate
progression-free rate at 12 months
Time frame: from baseline to 1 year follow up
Number of Participants with Adverse Events related to radiotherapy
adverse effects (acute toxicity) according to CTCAE-NCI
Time frame: from baseline to 1 year follow up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
* Sample T4: one week after the end of the radiotherapy, * Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy.